Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.
Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, Freeman GJ, Warren SE, Ong S, Browning E, Twitty CG, Pierce RH, Le MH, Algazi AP, Daud AI, Pai SI, Zippelius A, Weissleder R, Pittet MJ. Garris CS, et al. Among authors: twitty cg. Immunity. 2018 Dec 18;49(6):1148-1161.e7. doi: 10.1016/j.immuni.2018.09.024. Epub 2018 Dec 11. Immunity. 2018. PMID: 30552023 Free PMC article.
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma.
Algazi AP, Twitty CG, Tsai KK, Le M, Pierce R, Browning E, Hermiz R, Canton DA, Bannavong D, Oglesby A, Francisco M, Fong L, Pittet MJ, Arlauckas SP, Garris C, Levine LP, Bifulco C, Ballesteros-Merino C, Bhatia S, Gargosky S, Andtbacka RHI, Fox BA, Rosenblum MD, Daud AI. Algazi AP, et al. Among authors: twitty cg. Clin Cancer Res. 2020 Jun 15;26(12):2827-2837. doi: 10.1158/1078-0432.CCR-19-2217. Epub 2020 May 6. Clin Cancer Res. 2020. PMID: 32376655 Free PMC article. Clinical Trial.
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.
Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, Freeman GJ, Warren SE, Ong S, Browning E, Twitty CG, Pierce RH, Le MH, Algazi AP, Daud AI, Pai SI, Zippelius A, Weissleder R, Pittet MJ. Garris CS, et al. Among authors: twitty cg. Immunity. 2022 Sep 13;55(9):1749. doi: 10.1016/j.immuni.2022.07.021. Immunity. 2022. PMID: 36103861 No abstract available.
Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses.
Greaney SK, Algazi AP, Tsai KK, Takamura KT, Chen L, Twitty CG, Zhang L, Paciorek A, Pierce RH, Le MH, Daud AI, Fong L. Greaney SK, et al. Among authors: twitty cg. Cancer Immunol Res. 2020 Feb;8(2):246-254. doi: 10.1158/2326-6066.CIR-19-0359. Epub 2019 Dec 18. Cancer Immunol Res. 2020. PMID: 31852717 Free PMC article. Clinical Trial.
Prognostic Biomarkers for Melanoma Immunotherapy.
Twitty CG, Huppert LA, Daud AI. Twitty CG, et al. Curr Oncol Rep. 2020 Feb 11;22(3):25. doi: 10.1007/s11912-020-0886-z. Curr Oncol Rep. 2020. PMID: 32048065 Review.
Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma.
Bhatia S, Longino NV, Miller NJ, Kulikauskas R, Iyer JG, Ibrani D, Blom A, Byrd DR, Parvathaneni U, Twitty CG, Campbell JS, Le MH, Gargosky S, Pierce RH, Heller R, Daud AI, Nghiem P. Bhatia S, et al. Among authors: twitty cg. Clin Cancer Res. 2020 Feb 1;26(3):598-607. doi: 10.1158/1078-0432.CCR-19-0972. Epub 2019 Oct 3. Clin Cancer Res. 2020. PMID: 31582519 Free PMC article.
Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients.
Algazi A, Bhatia S, Agarwala S, Molina M, Lewis K, Faries M, Fong L, Levine LP, Franco M, Oglesby A, Ballesteros-Merino C, Bifulco CB, Fox BA, Bannavong D, Talia R, Browning E, Le MH, Pierce RH, Gargosky S, Tsai KK, Twitty C, Daud AI. Algazi A, et al. Ann Oncol. 2020 Apr;31(4):532-540. doi: 10.1016/j.annonc.2019.12.008. Epub 2020 Feb 1. Ann Oncol. 2020. PMID: 32147213 Free article. Clinical Trial.
Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity.
Lee JY, Nguyen B, Mukhopadhyay A, Han M, Zhang J, Gujar R, Salazar J, Hermiz R, Svenson L, Browning E, Lyerly HK, Canton DA, Fisher D, Daud A, Algazi A, Skitzki J, Twitty CG. Lee JY, et al. Among authors: twitty cg. Mol Ther Oncolytics. 2022 Apr 18;25:174-188. doi: 10.1016/j.omto.2022.04.005. eCollection 2022 Jun 16. Mol Ther Oncolytics. 2022. PMID: 35592387 Free PMC article.
22 results